| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SOX2 |
| Uniprot No | P48431 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-317aa |
| 氨基酸序列 | MYNMMETELK PPGPQQTSGG GGGNSTAAAA GGNQKNSPDR VKRPMNAFMV WSRGQRRKMA QENPKMHNSE ISKRLGAEWK LLSETEKRPF IDEAKRLRAL HMKEHPDYKY RPRRKTKTLM KKDKYTLPGG LLAPGGNSMA SGVGVGAGLG AGVNQRMDSY AHMNGWSNGS YSMMQDQLGY PQHPGLNAHG AAQMQPMHRY DVSALQYNSM TSSQTYMNGS PTYSMSYSQQ GTPGMALGSM GSVVKSEASS SPPVVTSSSH SRAPCQAGDL RDMISMYLPG AEVPEPAAPS RLHMSQHYQS GPVPGTAING TLPLSHM |
| 预测分子量 | 40.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Recombinant Human SOX2 Protein Expression and Purification in Escherichia coli"** - Chen et al.
摘要：研究利用原核表达系统(大肠杆菌)高效表达带有His标签的人源SOX2重组蛋白，通过亲和层析纯化，验证其与DNA结合活性，为干细胞研究提供工具。
2. **"Functional Characterization of Purified SOX2 in Pluripotency Maintenance"** - Cox & Guleria
摘要：通过哺乳动物细胞表达系统纯化SOX2重组蛋白，证明其在维持胚胎干细胞多能性中的关键作用，并揭示其与OCT4协同调控靶基因的分子机制。
3. **"SOX2 Recombinant Protein Enhances Direct Reprogramming of Somatic Cells"** - Kim et al.
摘要：报道SOX2重组蛋白与其它转录因子联用，显著提高成纤维细胞向诱导多能干细胞的转化效率，为无基因整合的重编程技术提供支持。
4. **"Structural and Biochemical Analysis of SOX2-DNA Interaction Using Recombinant Protein"** - Jang et al.
摘要：通过X射线晶体学解析SOX2重组蛋白与靶DNA复合物结构，揭示其特异性结合模式，为癌症中SOX2异常活化的治疗策略提供结构基础。
SOX2 (SRY-related HMG-box 2) is a transcription factor belonging to the SOX protein family, which plays a pivotal role in embryonic development and maintaining pluripotency. It is essential for the self-renewal of embryonic stem cells (ESCs) and the determination of cell fate during differentiation. SOX2 is particularly critical in early embryogenesis, such as neural ectoderm formation, and in sustaining the identity of progenitor cells in adult tissues, including the brain, retina, and respiratory epithelium. Dysregulation of SOX2 is linked to developmental disorders, cancer progression, and degenerative diseases.
Recombinant SOX2 protein is produced via molecular cloning techniques, typically expressed in bacterial or mammalian systems to ensure proper post-translational modifications. This engineered protein retains the functional domains of native SOX2. including the high-mobility group (HMG) DNA-binding domain, enabling it to interact with target gene promoters. Recombinant versions are standardized for purity and activity, making them valuable tools for studying mechanisms of pluripotency, cellular reprogramming, and disease pathways.
In research, recombinant SOX2 is widely used to induce pluripotent stem cells (iPSCs) when combined with other factors like OCT4. KLF4. and c-MYC. It also aids in modeling neurodevelopmental disorders and exploring regenerative therapies for conditions such as retinal degeneration or spinal cord injury. However, its oncogenic potential in certain contexts necessitates careful experimental design.
Commercial recombinant SOX2 often includes tags (e.g., His-tag) for purification and detection. Quality control involves assays verifying its ability to activate pluripotency genes or bind DNA sequences. Despite challenges in delivery and stability, recombinant SOX2 remains a cornerstone in developmental biology and translational medicine, bridging basic research and therapeutic innovation.
×
